RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS

被引：0

作者：

Raje, N. ^{[1
]}

Bensinger, W. ^{[2
]}

Lebovic, D. ^{[3
]}

Lonial, S. ^{[4
]}

Jagannath, S. ^{[5
]}

Acre-Lara, C. ^{[6
]}

Rosko, A. ^{[7
]}

Harb, W. ^{[8
]}

Bahlis, N. ^{[9
]}

Supko, J. ^{[1
]}

Tamang, D. ^{[10
]}

Jones, S. ^{[10
]}

Wheeler, C. ^{[10
]}

Richardson, P. ^{[11
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Univ Michigan, Ann Arbor, MI 48109 USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Mt Sinai Hosp, New York, NY 10029 USA

[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[7] Ohio State Univ, Columbus, OH 43210 USA

[8] Horizon Oncol Ctr, Lafayette, IN USA

[9] Tom Baker Canc Clin, Calgary, AB, Canada

[10] Acetylon Pharmaceut Inc, Boston, MA USA

[11] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P279

引用

页码：86 / 86

页数：1

共 50 条

[1] Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma
Yee, Andrew J.
Voorhees, Peter M.
Bensinger, William
Berdeja, Jesus G.
Supko, Jeffrey G.
Richardson, Paul G.
Tamang, David
Jones, Simon S.
Patrick, Gretchen
Wheeler, Catherine
Raje, Noopur
BLOOD, 2014, 124 (21)
[2] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)
Vogl, Dan T.
Raje, Noopur S.
Jagannath, Sundar
Richardson, Paul G.
Hari, Parameswaran
Orlowski, Robert Z.
Supko, Jeffrey
Tamang, David
Jones, Simon S.
Wheeler, Catherine
Markelewicz, Robert J., Jr.
Lonial, Sagar
BLOOD, 2015, 126 (23)
[3] Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)
Vogl, Dan T.
Raje, Noopur
Hari, Parameswaran
Jones, Simon S.
Supko, Jeffrey G.
Leone, Gina
Wheeler, Catherine
Orlowski, Robert Z.
Richardson, Paul G.
Lonial, Sagar
Tamang, David
Jagannath, Sundar
BLOOD, 2014, 124 (21)
[4] RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HDAC6 INHIBITOR, COMBINED WITH POMALIDOMIDE AND DEXAMETHASONE SHOWS PROMISING EARLY PHASE 2 RESULTS IN RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA: ACE-MM-102
Raje, N.
Terpos, E.
Cole, C.
Bahlis, N.
Bensinger, W.
Libby, E.
Palumbo, A.
Lonial, S.
Sandhu, I.
Arce-Lara, C.
Jagannath, S.
Valent, J.
Rosko, A.
Reece, D.
Supko, J.
Tamang, D.
Jones, S.
Wheeler, C.
Markelewicz, R.
Richardson, P.
HAEMATOLOGICA, 2016, 101 : 328 - 328
[5] PHASE 1B STUDY OF AN ALTERNATIVE LIQUID FORMULATION OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSEDAND- REFRACTORY MULTIPLE MYELOMA
Madan, S.
Atanackovic, D.
Supko, J.
Tamang, D.
Jones, S. S.
Wheeler, C.
Trede, N. S.
Anderson, L.
HAEMATOLOGICA, 2016, 101 : 254 - 254
[6] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed -and Refractory Multiple Myeloma: Phase lb Results (ACE-MM-101 Study)
Yee, Andrew J.
Bensinger, William
Voorhees, Peter M.
Berdeja, Jesus G.
Richardson, Paul G.
Supko, Jeffrey
Tamang, David
Jones, Simon S.
Wheeler, Catherine
Markelewicz, Robert J., Jr.
Raje, Noopur S.
BLOOD, 2015, 126 (23)
[7] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)
Raje, Noopur S.
Bensinger, William
Cole, Craig E.
Lonial, Sagar
Jagannath, Sundar
Arce-Lara, Carlos E.
Valent, Jason
Rosko, Ashley E.
Harb, Wael A.
Sandhu, Irwindeep
Bahlis, Nizar J.
Reece, Donna
Terpos, Evangelos
Supko, Jeffrey
Tamang, David
Jones, Simon S.
Wheeler, Catherine
Markelewicz, Robert J., Jr.
Richardson, Paul G.
BLOOD, 2015, 126 (23)
[8] Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma
Santo, Loredana
Hideshima, Teru
Kung, Andrew L.
Tseng, Jen-Chieh
Tamang, David
Yang, Min
Jarpe, Matthew
van Duzer, John H.
Mazitschek, Ralph
Ogier, Walter C.
Cirstea, Diana D.
Rodig, Scott
Eda, Homare
Scullen, Tyler A.
Canavese, Miriam
Bradner, James E.
Anderson, Kenneth C.
Jones, Simon
Raje, Noopur S.
BLOOD, 2011, 118 (21) : 1256 - 1256
[9] Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Santo, Loredana
Hideshima, Teru
Kung, Andrew L.
Tseng, Jen-Chieh
Tamang, David
Yang, Min
Jarpe, Matthew
van Duzer, John H.
Mazitschek, Ralph
Ogier, Walter C.
Cirstea, Diana
Rodig, Scott
Eda, Homare
Scullen, Tyler
Canavese, Miriam
Bradner, James
Anderson, Kenneth C.
Jones, Simon S.
Raje, Noopur
BLOOD, 2012, 119 (11) : 2579 - 2589
[10] RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA
Raje, N.
Vogl, D.
Bensinger, W.
Voorhees, P.
Hari, P.
Berdeja, J.
Jagannath, S.
Jones, S.
Wheeler, C.
Supko, J.
Orlowski, R.
Richardson, P.
Lonial, S.
HAEMATOLOGICA, 2014, 99 : 107 - 108

← 1 2 3 4 5 →